← Back to Search

LC542019 for Type 2 Diabetes

Phase 1
Waitlist Available
Research Sponsored by LG Chem
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 weeks
Awards & highlights

Summary

to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM).

Eligible Conditions
  • Type 2 Diabetes
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Other study objectives
Cardiodynamic evaluation

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LC542019Experimental Treatment1 Intervention
oral dose, once daily.
Group II: PlaceboPlacebo Group1 Intervention
matching placebo capsules.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LC542019
2022
Completed Phase 1
~100

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

LG ChemLead Sponsor
63 Previous Clinical Trials
33,341 Total Patients Enrolled
~29 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top